- Release Date: 16/05/13 16:36
- Summary: GENERAL: PEB: China Grants Patent for Detection of Gastric Cancer
- Price Sensitive: No
- Download Document 5.54KB
PEB 16/05/2013 14:36 GENERAL REL: 1436 HRS Pacific Edge Limited GENERAL: PEB: China Grants Patent for Detection of Gastric Cancer 16 May 2013 China grants Patent for Detection of Gastric Cancer China, with one of the highest incidences of stomach (Gastric) cancer in the world, has granted Pacific Edge Limited (the Company) its patent, 'Detection of Gastric Cancer'. This patent defines technology that can be used for the diagnosis of gastric cancer. The granting of the Company's patent in China is a further addition to the Company's suite of intellectual property that includes accurate tests for the diagnosis and prognosis of several hard to detect cancers including those of the bladder, alimentary tract, stomach and melanomas. Earlier this year, Pacific Edge achieved a significant milestone in the commercialisation of its molecular diagnostic technology with regulatory approval to launch Cxbladder, its non-invasive detection test for bladder cancer, in the world's largest health market, the United States. In addition to the recent approval in the USA, Cxbladder is now being marketed in New Zealand and Australia and soon in Spain, which has the world's highest incidence of bladder cancer. Pacific Edge now has patent rights for its patent 'Detection of Gastric Cancer', in New Zealand, Australia and Europe in addition to China. Further issuances for this patent are expected in other key geographies in the near future. Gastric cancer is one of the most frequent cancers in the world only exceed by lung, breast and colorectal cancers. Almost two-thirds of gastric cancer cases and deaths occur in less developed regions, including East Asia and South America. In China, there are approximately 400,000 new cases of gastric cancer a year detected and 300,000 deaths. Pacific Edge Chief Executive Officer David Darling says investment in intellectual property is a significant annual investment for the Company and underpins the commercial capability of the Company's products. For further information please contact David Darling Chief Executive Officer Pacific Edge Limited P: +64 (3) 4795800 ABOUT PACIFIC EDGE Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. Products in development and in clinical trials are accurate and simple to use genomic and proteomic tools for the earlier detection, improved characterisation and better management of gastric, bladder, colorectal cancers and melanoma. The Company has recently completed and released its first product for the detection of bladder cancer, Cxbladder, and is actively marketing the product to urologists in New Zealand, Australia and soon to be Spain and the USA. www.pacificedge.co.nz ABOUT PACIFIC EDGE DIAGNOSTICS Pacific Edge takes its exciting cancer detection tests to market through its wholly owned subsidiaries, Pacific Edge Diagnostics NZ Limited and Pacific Edge Diagnostics USA Limited, and selected commercial partners in Australia and Spain, Healthscope Pathology and Oryzon respectively. www.pacificedgedx.com ABOUT Cxbladder Cxbladder is a non-invasive, accurate test that enables the early detection of bladder cancer from a small volume of urine. It provides general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy. The recently published, Journal of Urology in September 2012, multi-centre international clinical study recruited 485 patients from Australia and New Zealand. Results show that Cxbladder out-performed all other benchmark technologies in the clinical trial and detected nearly all of the tumours of concern to a urologist; At 85% specificity the test sees 100% of T1, T2, T3, Tis and greater than 95% of high grade tumours. www.cxbladder.com ABOUT BLADDER CANCER Globally, bladder cancer has the 9th highest incidence and the 4th highest incidence for men. One of the early symptoms of bladder cancer is the presence of blood in the urine, haematuria. People with haematuria often present to their general practitioner before being referred on to a urologist. There are a number of 'at risk' occupations that have shown a much higher incidence of bladder cancer. Fire fighters and fire control officers have shown in a US study to have a twice the incidence of bladder cancer over non fire fighters. Smoking is a significant contributing factor (over 50% in males and 33% in females, and approximately one of every two new incidences of bladder cancer is linked to smoking). Exposure to certain industrial chemicals or carcinogens increases risks for some occupations e.g. hairdressers, painters, printers, fire fighters and metal workers and chemical engineers. Incidence increases with age so the older you are, the greater the potential for bladder cancer. Bladder cancer has a very high recurrence rate of approximately 50%-70% with up to 30% of these recurring as later stage tumours. This is a higher recurrence than for skin cancer! However, bladder cancers are highly treatable, especially if detected in the early stages. If diagnosed early there is a much higher probability of survival for early stage tumours relative to later stage tumours. This makes timely and regular surveillance and monitoring of this cancer a key element of the clinical process and of the individual's annual healthcare plan. End CA:00236315 For:PEB Type:GENERAL Time:2013-05-16 14:36:35
Add to My Watchlist
What is My Watchlist?
